Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTLT Catalent	$63.48	$62.87	$56.25 ▼ $63.50	$11.52B	1.15	2.04 million shs	N/A
IONS Ionis Pharmaceuticals	$43.59 +9.1%	$34.70	$23.95 ▼ $52.34	$6.36B	0.23	1.60 million shs	4.23 million shs
JAZZ Jazz Pharmaceuticals	$109.92 +0.4%	$108.98	$95.49 ▼ $148.06	$6.62B	0.32	828,820 shs	774,709 shs
OPHLF Ono Pharmaceutical	$9.33	$10.89	$9.20 ▼ $16.05	$4.38B	0.49	1,227 shs	N/A
PRGO Perrigo	$27.23 -0.7%	$26.45	$23.14 ▼ $30.93	$3.77B	0.45	1.46 million shs	1.43 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTLT Catalent	0.00%	0.00%	0.00%	0.00%	+13.01%
IONS Ionis Pharmaceuticals	+1.09%	+0.76%	+18.73%	+39.12%	-15.22%
JAZZ Jazz Pharmaceuticals	+3.13%	+1.23%	+1.07%	-13.45%	+2.79%
OPHLF Ono Pharmaceutical	0.00%	-12.89%	-10.10%	-0.74%	-32.97%
PRGO Perrigo	+2.41%	+2.24%	+2.11%	-1.92%	+4.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTLT Catalent	1.0744 of 5 stars	1.0	0.0	0.0	4.6	0.0	0.0	1.9
IONS Ionis Pharmaceuticals	4.6029 of 5 stars	4.4	2.0	0.0	3.0	2.6	3.3	0.6
JAZZ Jazz Pharmaceuticals	4.9285 of 5 stars	4.5	1.0	0.0	4.0	3.4	3.3	2.5
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	4.9506 of 5 stars	2.1	5.0	4.2	3.5	2.7	1.7	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTLT Catalent	2.00	Hold	$63.50	0.03% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$58.25	33.63% Upside
JAZZ Jazz Pharmaceuticals	2.92	Moderate Buy	$184.00	67.39% Upside
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A
PRGO Perrigo	2.25	Hold	$33.00	21.19% Upside

Current Analyst Ratings Breakdown

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00
6/11/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
6/3/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$182.00 ➝ $172.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$167.00 ➝ $155.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$176.00 ➝ $147.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$183.00 ➝ $166.00
5/7/2025	JAZZ Jazz Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$200.00 ➝ $200.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTLT Catalent	$4.38B	2.63	$2.64 per share	24.04	$19.91 per share	3.19
IONS Ionis Pharmaceuticals	$705M	9.84	N/A	N/A	$3.73 per share	11.69
JAZZ Jazz Pharmaceuticals	$4.07B	1.63	$30.45 per share	3.61	$67.72 per share	1.62
OPHLF Ono Pharmaceutical	$3.20B	1.37	$1.08 per share	8.66	$11.07 per share	0.84
PRGO Perrigo	$4.37B	0.86	$5.01 per share	5.43	$31.66 per share	0.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTLT Catalent	-$1.04B	-$2.26	N/A	47.02	2.69	-9.28%	-0.66%	-0.24%	N/A
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	14.66	5.87	4.72	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
OPHLF Ono Pharmaceutical	$330.31M	$0.70	13.33	∞	N/A	10.24%	6.20%	4.66%	7/28/2025 (Estimated)
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.90	N/A	-4.16%	8.93%	3.87%	8/1/2025 (Estimated)

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	N/A	N/A	N/A	$1.05 billion	N/A
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTLT Catalent	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.26%	N/A	N/A	23 Years

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTLT Catalent	1.38	2.51	1.96
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
OPHLF Ono Pharmaceutical	0.13	3.07	2.56
PRGO Perrigo	0.82	2.36	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTLT Catalent	N/A
IONS Ionis Pharmaceuticals	93.86%
JAZZ Jazz Pharmaceuticals	89.14%
OPHLF Ono Pharmaceutical	N/A
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
CTLT Catalent	0.31%
IONS Ionis Pharmaceuticals	2.60%
JAZZ Jazz Pharmaceuticals	4.30%
OPHLF Ono Pharmaceutical	N/A
PRGO Perrigo	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTLT Catalent	16,900	181.51 million	180.95 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	155.02 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable
PRGO Perrigo	8,379	137.48 million	136.52 million	Optionable

IONS, JAZZ, PRGO, CTLT, and OPHLF Headlines

Recent News About These Companies

Perrigo Announces Leadership Change Amid Strategic Update

July 1 at 6:03 PM | tipranks.com

Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance

July 1 at 4:30 PM | prnewswire.com

Good Start® | Dr. Brown's™ Launches 30-Day "Gentle Baby Formula Giveaway Contest" with a Generous Donation to Baby2Baby

July 1 at 9:02 AM | prnewswire.com

Allspring Global Investments Holdings LLC Has $31.65 Million Position in Perrigo Company plc (NYSE:PRGO)

July 1 at 4:48 AM | marketbeat.com

Copeland Capital Management LLC Has $68.78 Million Position in Perrigo Company plc (NYSE:PRGO)

June 28, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Cut to "Hold" at Wall Street Zen

June 28, 2025 | americanbankingnews.com

Wall Street Zen Downgrades Perrigo (NYSE:PRGO) to Hold

June 27, 2025 | marketbeat.com

Perpetual Ltd Sells 486,454 Shares of Perrigo Company plc (NYSE:PRGO)

June 27, 2025 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Shares Sold by Janney Montgomery Scott LLC

June 27, 2025 | marketbeat.com

Boyar Asset Management Inc. Takes $734,000 Position in Perrigo Company plc (NYSE:PRGO)

June 26, 2025 | marketbeat.com

Lecap Asset Management Ltd. Takes $724,000 Position in Perrigo Company plc (NYSE:PRGO)

June 26, 2025 | marketbeat.com

PRGO - Perrigo Co PLC Chart - Morningstar

June 25, 2025 | morningstar.comM

Should Value Investors Buy Perrigo (PRGO) Stock?

June 23, 2025 | zacks.com

February 2026 Options Now Available For Perrigo (PRGO)

June 20, 2025 | nasdaq.com

These 3 Dividend Stocks Combine Strong Yields With Upside

...

June 20, 2025 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Shares Acquired by SG Americas Securities LLC

June 16, 2025 | marketbeat.com

Sound Income Strategies LLC Buys 15,265 Shares of Perrigo Company plc (NYSE:PRGO)

June 15, 2025 | marketbeat.com

Perrigo Company plc (NYSE:PRGO) Shares Acquired by GAMMA Investing LLC

June 13, 2025 | marketbeat.com

Does Perrigo (PRGO) Have the Potential to Rally 32.86% as Wall Street Analysts Expect?

June 11, 2025 | zacks.com

54,428 Shares in Perrigo Company plc (NYSE:PRGO) Acquired by Beach Investment Counsel Inc. PA

June 8, 2025 | marketbeat.com

NBC Securities Inc. Grows Stake in Perrigo Company plc (NYSE:PRGO)

June 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
By Sarah Horvath | June 9, 2025
View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside
3 Growth Stocks Too Small for Institutions to Buy
By Gabriel Osorio-Mazilli | June 19, 2025
View 3 Growth Stocks Too Small for Institutions to Buy

IONS, JAZZ, PRGO, CTLT, and OPHLF Company Descriptions

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Ionis Pharmaceuticals NASDAQ:IONS

$43.59 +3.65 (+9.14%)

Closing price 04:00 PM Eastern

Extended Trading

$43.42 -0.17 (-0.39%)

As of 07:13 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Jazz Pharmaceuticals NASDAQ:JAZZ

$109.92 +0.48 (+0.44%)

Closing price 04:00 PM Eastern

Extended Trading

$108.47 -1.45 (-1.32%)

As of 04:42 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Ono Pharmaceutical OTCMKTS:OPHLF

$9.33 0.00 (0.00%)

As of 07/1/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Perrigo NYSE:PRGO

$27.23 -0.20 (-0.73%)

Closing price 03:59 PM Eastern

Extended Trading

$27.26 +0.03 (+0.11%)

As of 06:09 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Earnings

Compare Dividends

Latest IONS, JAZZ, PRGO, CTLT, and OPHLF Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, JAZZ, PRGO, CTLT, and OPHLF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, JAZZ, PRGO, CTLT, and OPHLF Company Descriptions

Catalent NYSE:CTLT

Ionis Pharmaceuticals NASDAQ:IONS

Jazz Pharmaceuticals NASDAQ:JAZZ

Ono Pharmaceutical OTCMKTS:OPHLF

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools